INCYTE CORP
Ticker: INCYIndustrialsProfessional ServicesS&P 500The business
Incyte Corporation (NASDAQ: INCY) is a global biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary therapeutics. The company maintains research and commercial operations across multiple continents, with significant facilities in Wilmington, Delaware, Morges, Switzerland, Tokyo, Japan, and Montreal, Canada. Incyte's website is www.incyte.com.
The company operates across three primary therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. In Hematology, Incyte commercializes JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease, along with ICLUSIG (ponatinib), MONJUVI/MINJUVI (tafasitamab), and NIKTIMVO (axatilimab). The Oncology franchise includes PEMAZYRE (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms, and ZYNYZ (retifanlimab) for Merkel cell carcinoma and squamous cell carcinoma of the anal canal. The Inflammation and Autoimmunity segment features OPZELURA (ruxolitinib) cream for atopic dermatitis and vitiligo.
Incyte's business model combines internal drug discovery with strategic collaborations and licensing arrangements. The company maintains exclusive development and commercialization rights to JAKAFI in the United States while licensing ruxolitinib internationally to Novartis under the brand name JAKAVI. Similarly, baricitinib is licensed to Eli Lilly for inflammatory and autoimmune indications, and capmatinib is licensed to Novartis for oncology applications. These arrangements generate milestone payments and royalty revenues.
The company's competitive advantages include proprietary expertise in medicinal chemistry, biologics, and targeted drug discovery, supported by comprehensive in-house capabilities spanning target validation, high-throughput screening, structural biology, and computational drug discovery. Incyte emphasizes a focused pipeline strategy, concentrating resources on selected programs in targeted oncology, myeloid diseases, and dermatology. The company collaborates with academic institutions, contract research organizations, and biotechnology partners to enhance its development capabilities while maintaining control over key therapeutic areas and markets where it believes it can successfully compete.
- Sector
- Industrials
- Industry
- Professional Services
- HQ
- WILMINGTON, DE
- FY end
- 12-31
- CIK
- 879169
- SIC
- 8731
Ownership
Who holds INCYTE CORP — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| Dodge & Cox Stock Fund DODGX · Dodge & Cox Funds | 0.76% | $901.57M |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.03% | $611.11M |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.03% | $492.77M |
| VANGUARD SMALL-CAP INDEX FUND VB · VANGUARD INDEX FUNDS | 0.23% | $441.46M |
| iShares Core S&P 500 ETF IVV · iShares Trust | 0.03% | $261.84M |
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of INCYTE CORP's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free